Next Article in Journal
A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma
Previous Article in Journal
Evaluation of Tumor Control and Normal Tissue Complication Probabilities in Patients Receiving Comprehensive Nodal Irradiation for Left-Sided Breast Cancer
Previous Article in Special Issue
Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?

1
Inserm CIC 1413, Hépato-Gastroentérologie, Institut des Maladies de l’Appareil Digestif (IMAD), CHU Nantes, Nantes Université, 44000 Nantes, France
2
Department of Radiation Oncology, Institut de Cancérologie de l’Ouest, Bd Professeur Jacques Monod, 44800 Saint-Herblain, France
3
Department of Radiology, University Hospital, Nantes 1 Place Alexis Ricordeau, 44093 Nantes, France
4
Nuclear Medicine Department, University Hospital, 44093 Nantes, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2024, 31(6), 3199-3211; https://doi.org/10.3390/curroncol31060242
Submission received: 10 April 2024 / Revised: 17 May 2024 / Accepted: 29 May 2024 / Published: 31 May 2024

Abstract

Hepatocellular carcinoma (HCC) is a disease with a poor prognosis, often diagnosed at an advanced stage. Therapeutic options have developed considerably in recent years, particularly with trans-arterial treatments. Systemic treatments have also evolved significantly, with the rise of immune checkpoint inhibitors (ICI) as first-line treatment for advanced HCC. The combination of loco-regional treatments and ICI is opening up new prospects and is the subject of numerous clinical trials. Recently, two global phase 3 trials investigating ICI-based adjuvant combinations have demonstrated improvements in recurrence-free survival or progression-free survival in patients treated with resection, ablation, or trans-arterial chemoembolization. However, mature data and overall survival results are still awaited but will be difficult to interpret. We are at the start of a new era of combinations of loco-regional treatments and immunotherapy. The identification of the best therapeutic strategies and predictive biomarkers is a crucial issue for future standards in clinical practice.
Keywords: hepatocellular carcinoma; locoregional treatment; adjuvant therapy; radio-frequency ablation; trans-arterial chemoembolization; selective internal radiation therapy; immune checkpoint inhibitors hepatocellular carcinoma; locoregional treatment; adjuvant therapy; radio-frequency ablation; trans-arterial chemoembolization; selective internal radiation therapy; immune checkpoint inhibitors

Share and Cite

MDPI and ACS Style

Boilève, J.; Guimas, V.; David, A.; Bailly, C.; Touchefeu, Y. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time? Curr. Oncol. 2024, 31, 3199-3211. https://doi.org/10.3390/curroncol31060242

AMA Style

Boilève J, Guimas V, David A, Bailly C, Touchefeu Y. Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time? Current Oncology. 2024; 31(6):3199-3211. https://doi.org/10.3390/curroncol31060242

Chicago/Turabian Style

Boilève, Juliette, Valentine Guimas, Arthur David, Clément Bailly, and Yann Touchefeu. 2024. "Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?" Current Oncology 31, no. 6: 3199-3211. https://doi.org/10.3390/curroncol31060242

Article Metrics

Back to TopTop